Mark D. Vincent - 19 Jan 2023 Form 4 Insider Report for Aptose Biosciences Inc. (APTOF)

Role
Director
Signature
/s/ Fletcher Payne as attorney-in-fact for Mark D. Vincent
Issuer symbol
APTOF
Transactions as of
19 Jan 2023
Net transactions value
$0
Form type
4
Filing time
23 Jan 2023, 19:04:46 UTC
Previous filing
20 Jan 2022
Next filing
07 Feb 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APTO Director Stock Option (Right to Buy) Award $0 +100,000 $0.000000 100,000 19 Jan 2023 Common Shares 100,000 $0.6600 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Fifty percent (50%) of the options vest on January 19, 2024, twenty-five percent (25%) vest on January 19, 2025, and twenty-five percent (25%) vest on January 19, 2026.